Fenwick represents Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced IP diligence...
This content is for Standard 1 Year members only. LoginJoin Now